Results from the Women’s Health Study, a randomized 2 × 2 factorial trial evaluating the benefits and risks of taking aspirin every other day (100 mg) and natural-source vitamin E (600 IU) vs placebo in the primary prevention of cardiovascular disease (CVD) and cancer, are reported in 2 articles Article Article in this issue of JAMA. The investigators found that compared with placebo, neither aspirin nor vitamin E was associated with reductions in overall or site-specific cancer incidence, cancer mortality, major cardiovascular events, or cardiovascular and total mortality. In editorials, Jacobs and Thun Article discuss the challenges of cancer chemoprevention and Redberg Article discusses CVD prevention strategies for women.
The utility of the prostate-specific antigen (PSA) test to identify men with prostate cancer is controversial. Thompson and colleagues Article assessed the performance characteristics of PSA screening in men who had PSA values of 3.0 ng/mL or less at baseline, who had annual PSA measurement through 7 years of follow-up, and who underwent an end-of-study prostate biopsy. The authors found that no specific value of PSA had both high sensitivity and specificity for prostate cancer. Rather, there was a continuum of cancer risk at all values of PSA and no definitive PSA level at which to recommend prostate biopsy.
Some evidence suggests an increased risk of mortality in patients with hyperthyroidism, but whether this risk derives from the effects of excess thyroid hormone, the hypothyroid state following treatment, or its reversal with thyroid hormone (thyroxine [T4]) therapy is not clear. To address this question, Franklyn and colleagues Article investigated mortality in a cohort of individuals treated with radioiodine for overt hyperthyroidism. They found an increased risk of all-cause and circulatory deaths during follow-up in patients who did not require or had not yet started T4 therapy. There was no increased risk of mortality during follow-up among patients who received T4 for radioiodine-induced hypothyroidism.
Grahic Jump Location
Elevated arginase activity has been reported in sickle cell disease. Morris and colleagues Article hypothesized that increased arginase activity and dysregulated arginine metabolism contribute to sickle cell disease pathogenesis, morbidity, and mortality and tested their hypothesis in 228 patients with sickle cell disease and 36 African American controls. They found that plasma arginase levels were significantly higher in patients compared with controls and that lower levels of plasma arginine were associated with a greater severity of pulmonary hypertension and higher mortality.
“Darkness, both physical and spiritual, descends upon our unit. Many, both physician and nurse, have never seen anything like this.” From “Death and Life in Iraq.”
See Article
Interest in discovering compounds that reduce cancer risk has never been higher, but identifying safe and effective chemopreventive agents has proved expectedly difficult.
Measures of serum testosterone, free testosterone, androstenedione, or dehydroepiandrosterone sulfate do not correlate with self-reports of low sexual function in women.
Individuals consuming at least 4 to 6 cups of coffee daily may have a reduced risk of type 2 diabetes.
A review and update of JAMA policies regarding authors’ conflicts of interest, disclosures of financial, material, or other paid support of their research, and requirements for reporting industry-sponsored studies.
For your patients: Information about hyperthyroidism.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.